the systemic administration of lymphokine activated killer ( lak ) cells and recombinant interleukin-2 ( ril-2 ) is effective in reducing the number of established pulmonary and hepatic metastases from multiple murine tumors and has recently been shown to be effective in mediating the regression of metastatic cancer in humans as well .
C0021756
recombinant interleukin-2
C0086418
humans